WO2006113681A3 - Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation - Google Patents

Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2006113681A3
WO2006113681A3 PCT/US2006/014503 US2006014503W WO2006113681A3 WO 2006113681 A3 WO2006113681 A3 WO 2006113681A3 US 2006014503 W US2006014503 W US 2006014503W WO 2006113681 A3 WO2006113681 A3 WO 2006113681A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
novel plant
plant derived
plant
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/014503
Other languages
English (en)
Other versions
WO2006113681A2 (fr
Inventor
Felipe Jimenez
Thomas F. Mitts
Aleksander Hinek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Human Matrix Sciences LLC
Original Assignee
Hospital for Sick Children HSC
Human Matrix Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children HSC, Human Matrix Sciences LLC filed Critical Hospital for Sick Children HSC
Priority to JP2008506820A priority Critical patent/JP5118018B2/ja
Priority to CA2605078A priority patent/CA2605078C/fr
Priority to EP06750521A priority patent/EP1877079A4/fr
Publication of WO2006113681A2 publication Critical patent/WO2006113681A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006113681A3 publication Critical patent/WO2006113681A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention a trait à de nouveaux peptides et peptidomimétiques de type élastine dérivés de plantes pouvant servir de ligands fonctionnels pour des récepteurs d'élastine et la stimulation d'élastogenèse. Les nouveaux peptides dérivés de plantes fournissent une source alternative (d'origine non animale) de peptides contenant la séquence de GXXPG (SEQ ID NO. 2). La présente invention a également trait à des compositions thérapeutiques contenant de nouveaux peptides et peptidomimétiques dérivés de plantes utiles dans la stimulation d'élastogenèse et la dilatation capillaire. Les compositions thérapeutiques de la présente invention comportant de nouveaux peptides ou peptidomimétiques dérivés de plantes peuvent être combinées avec d'autres agents thérapeutiques.
PCT/US2006/014503 2005-04-15 2006-04-17 Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation Ceased WO2006113681A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008506820A JP5118018B2 (ja) 2005-04-15 2006-04-17 植物由来のエラスチン結合タンパク質リガンドおよびその使用方法
CA2605078A CA2605078C (fr) 2005-04-15 2006-04-17 Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation
EP06750521A EP1877079A4 (fr) 2005-04-15 2006-04-17 Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67155705P 2005-04-15 2005-04-15
US60/671,557 2005-04-15
US73758605P 2005-11-17 2005-11-17
US60/737,586 2005-11-17

Publications (2)

Publication Number Publication Date
WO2006113681A2 WO2006113681A2 (fr) 2006-10-26
WO2006113681A3 true WO2006113681A3 (fr) 2010-09-02

Family

ID=37115848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/014503 Ceased WO2006113681A2 (fr) 2005-04-15 2006-04-17 Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation

Country Status (5)

Country Link
US (6) US7723308B2 (fr)
EP (2) EP2460815B1 (fr)
JP (2) JP5118018B2 (fr)
CA (1) CA2605078C (fr)
WO (1) WO2006113681A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073616A2 (fr) 2003-02-14 2004-09-02 Human Matrix Sciences Llc Compositions a base d'un produit de digestion d'elastine et leurs methodes d'utilisation
US7803522B2 (en) 2004-02-13 2010-09-28 Human Matrix Sciences, Llc Elastin producing fibroblast formulations and methods of using the same
US7723308B2 (en) 2005-04-15 2010-05-25 Human Matrix Sciences, Llc Plant-derived elastin binding protein ligands and methods of using the same
US8114829B2 (en) * 2005-02-22 2012-02-14 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
US8642578B2 (en) 2005-03-29 2014-02-04 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
WO2006125049A2 (fr) 2005-05-17 2006-11-23 Human Matrix Sciences, Llc Formulations de fibroblastes produisant de l'elastine et procedes d'utilisation de celles-ci
CA2681110A1 (fr) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthese de benzothiazole diamines substituees et purifiees du point de vue chiral
KR20110071064A (ko) 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
FR2957252B1 (fr) * 2010-03-09 2016-04-08 Lvmh Rech Composition cosmetique
ES2397890B1 (es) * 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
FR2975292B1 (fr) * 2011-05-19 2013-12-20 Univ Reims Champagne Ardenne U R C A Utilisation de la kappa-elastine pour la reparation et/ou la regeneration des tissus parodontaux
WO2013096816A1 (fr) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Synthèse améliorée de composés substitués par amine de 4,5,6,7-tétrahydrobenzothiazole
US9387194B2 (en) 2012-01-18 2016-07-12 Human Matrix Sciences, Llc Sodium ascorbate stimulation of elastogenesis
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
EP3838271B1 (fr) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Traitement de taux élevés d'éosinophiles et/ou de basophiles
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (fr) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions et methodes pour le traitement de l'urticaire chronique
JP6145181B2 (ja) * 2016-01-14 2017-06-07 花王株式会社 Ｍｆａｐ−４産生促進剤
KR102014467B1 (ko) * 2017-12-14 2019-08-26 (주)녹십자웰빙 아토피성 피부염, 탈모, 상처 또는 피부 주름의 개선용 화장료 조성물 및 약학 조성물
CA3127450A1 (fr) * 2019-01-22 2020-07-30 Clemson University Research Foundation Anticorps anti-elastine et methodes d'utilisation
CA3149581A1 (fr) * 2019-08-30 2021-03-04 Gert Wensvoort Peptide q-er
CN116970071B (zh) * 2023-09-22 2023-12-01 英特菲尔(成都)生物制品有限责任公司 一种具有抗衰活性的重组弹性蛋白及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054021A1 (en) * 2001-06-14 2003-03-20 Maria Dalko 7-oxo-DHEA compounds for treating keratinous conditions/afflictions
US6964954B2 (en) * 2001-10-25 2005-11-15 L'oreal Use of DHEA derivatives on keratinous substances

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541463A (en) 1975-10-11 1979-02-28 Lion Dentifrice Co Ltd Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase
US5296500A (en) 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
US5834184A (en) * 1995-05-17 1998-11-10 Harada; Kazuo In vivo selection of RNA-binding peptides
CA2340686A1 (fr) * 1998-09-03 2000-03-16 Samantha J. Busfield Nouvelles molecules de la famille des proteines associees au mediateur d'entree du virus de l'herpes et leurs applications
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6812025B2 (en) * 2000-06-06 2004-11-02 The Trustees Of Columbia University In The City Of New York Two hybrid assay that detects HIV-1 reverse transcriptase dimerization
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
JP4519461B2 (ja) * 2001-07-31 2010-08-04 ユニヴァーシティ オブ ワシントン 免疫学的に重要な単純ヘルペスウイルス抗原およびそれを用いる方法
US20050100963A1 (en) * 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1578352A2 (fr) 2002-03-27 2005-09-28 University of Utah Research Foundation Elastine empechant l'occlusion de vaisseaux sanguins par des cellules de muscle lisse
GB0217033D0 (en) * 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
CA2511665A1 (fr) * 2002-12-18 2004-07-01 Novartis Ag Peptides a liaison specifique a des cellules endotheliales
WO2004073616A2 (fr) * 2003-02-14 2004-09-02 Human Matrix Sciences Llc Compositions a base d'un produit de digestion d'elastine et leurs methodes d'utilisation
FR2854897B1 (fr) * 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
US7723308B2 (en) * 2005-04-15 2010-05-25 Human Matrix Sciences, Llc Plant-derived elastin binding protein ligands and methods of using the same
US7803522B2 (en) 2004-02-13 2010-09-28 Human Matrix Sciences, Llc Elastin producing fibroblast formulations and methods of using the same
US7666829B2 (en) 2004-02-20 2010-02-23 Human Matrix Sciences, Llc Compositions for elastogenesis and connective tissue treatment
JP3927975B2 (ja) * 2004-09-13 2007-06-13 セムバイオシス ジェネティック インコーポレイテッド 植物中の高価値ペプチドの担体用の油体タンパク質
US7566693B2 (en) 2005-02-22 2009-07-28 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
US8642578B2 (en) 2005-03-29 2014-02-04 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
US20140100710A1 (en) 2012-10-05 2014-04-10 Ford Global Technologies Method and system for determining a primary direction of force resulting from a vehicle collision

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054021A1 (en) * 2001-06-14 2003-03-20 Maria Dalko 7-oxo-DHEA compounds for treating keratinous conditions/afflictions
US6964954B2 (en) * 2001-10-25 2005-11-15 L'oreal Use of DHEA derivatives on keratinous substances

Also Published As

Publication number Publication date
US20170002047A1 (en) 2017-01-05
CA2605078C (fr) 2013-01-08
EP1877079A4 (fr) 2011-08-31
EP2460815A1 (fr) 2012-06-06
US9422334B2 (en) 2016-08-23
US20090082280A1 (en) 2009-03-26
JP2008537962A (ja) 2008-10-02
CA2605078A1 (fr) 2006-10-26
US10844101B2 (en) 2020-11-24
US8524210B2 (en) 2013-09-03
US20110237516A1 (en) 2011-09-29
JP5118018B2 (ja) 2013-01-16
JP5814177B2 (ja) 2015-11-17
EP2460815B1 (fr) 2015-06-03
WO2006113681A2 (fr) 2006-10-26
US20140100170A1 (en) 2014-04-10
JP2012184239A (ja) 2012-09-27
US20210277072A1 (en) 2021-09-09
US20190153045A1 (en) 2019-05-23
US10167325B2 (en) 2019-01-01
US7723308B2 (en) 2010-05-25
EP1877079A2 (fr) 2008-01-16

Similar Documents

Publication Publication Date Title
WO2006113681A3 (fr) Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
TW200602052A (en) Azaindoles useful as inhibitors of JAK and other protein kinases
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
WO2009067639A3 (fr) Variantes de peptide natriurétique de type c
WO2008093060A3 (fr) Peptides et leur utilisation
WO2009004315A8 (fr) Peptides isolés et leurs utilisations
WO2006017538A3 (fr) Proteines de liaison a la proteine hk1
ZA201001054B (en) Peptide with reduced dimer formation
WO2007035716A3 (fr) Compositions de proteines rap specifiques des proteines contenant du cr, et leurs utilisations
PL1972637T3 (pl) Antagoniści selektywni wobec huTNFR1
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
WO2008093058A3 (fr) Peptides et leur utilisation
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
WO2006010070A3 (fr) Compositions et procedes lies a des peptides se liant de facon selective avec des cellules de la leucemie
WO2009138494A3 (fr) Séquences d'acides aminés dirigées contre des récepteurs du type toll et polypeptides comprenant celles-ci pour le traitement de maladies apparentées aux récepteurs du type toll
WO2007134118A3 (fr) Composition à base de protéines et méthodes d'utilisation
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
EA200600561A1 (ru) Фармацевтический препарат для лечения шока
EP1978994A4 (fr) Compositions à base de variantes de bmp-7, procédés et utilisations
ATE480552T1 (de) Stq-peptide
TW200626073A (en) Activated globular protein and its use in edible compositions
WO2007013358A3 (fr) Polypeptides vivit, agent therapeutique les contenant et methode de recherche par criblage d'agent anticancer
WO2006122162A3 (fr) Procede et composition pour traiter la mucosite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008506820

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2605078

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006750521

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU